Key result
Exome-derived high genetic Lp(a) risk is linked to earlier and more frequent ASCVD.
Why the study?
Does estimating Lp(a) from exome data identify individuals at high risk for ASCVD across a diverse cohort?
Cohort (n=76,147)
Does estimating Lp(a) from exome data identify individuals at high risk for ASCVD across a diverse cohort?
Answers are grounded in this paper and cite their sources.
A novel genomic method for estimating Lp(a) from exome data successfully identifies individuals at high risk for ASCVD, particularly those of non-European descent and those lacking traditional risk factors.
Lipoprotein(a) (Lp[a]) is a genetic and often unmeasured contributor to atherosclerotic cardiovascular disease (ASCVD) risk. In this study, Lp(a) was estimated from exome data by quantifying Kringle IV subtype 2 repeats alongside a single-nucleotide variant-based genetic risk score. This method was applied to a diverse cohort (N = 76,147) from the Helix Research Network. The method better identified individuals with high Lp(a) levels, especially among individuals not genetically similar to Europeans. High genetic risk for high Lp(a) level was correlated with earlier and more frequent ASCVD diagnoses. Those with high genetic Lp(a) were more likely to have ASCVD without traditional risk factors present.
No takes yet. Share an insight, caveat, or question.
Telis et al. (2025) conducted a cohort in Atherosclerotic cardiovascular disease (ASCVD) (n=76,147). High genetic risk for high Lp(a) level vs. Lower genetic risk for high Lp(a) level was evaluated on ASCVD diagnoses. High genetic risk for high Lp(a) levels estimated from exome data was correlated with earlier and more frequent ASCVD diagnoses, even in the absence of traditional risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: